The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
In β-thalassemia, ineffective erythropoiesis leads to anemia and systemic iron overload. The management of iron overload by chelation therapy is a standard of care. However, iron chelation does not improve the ineffective erythropoiesis. We recently showed that the oral ferroportin inhibitor VIT-276...
Main Authors: | Naja Nyffenegger, Anna Flace, Cédric Doucerain, Franz Dürrenberger, Vania Manolova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/2/873 |
Similar Items
-
Editorial: Stress erythropoiesis
by: Jaira Ferreira de Vasconcellos, et al.
Published: (2023-02-01) -
Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice
by: Wenbin An, et al.
Published: (2023-12-01) -
The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
by: Simon Grootendorst, et al.
Published: (2021-02-01) -
The Roles of Mitophagy and Autophagy in Ineffective Erythropoiesis in β-Thalassemia
by: Pornthip Chaichompoo, et al.
Published: (2022-09-01) -
Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?
by: Filomena Longo, et al.
Published: (2022-08-01)